A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05025085. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.
Study identification
- NCT ID
- NCT05025085
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2021
- Primary completion
- Jul 10, 2023
- Completion
- Mar 31, 2024
- Last update posted
- Oct 14, 2025
2021 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 165 | Grand Rapids | Michigan | 49546 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Local Institution - 024 | Southfield | Michigan | 48075 | — |
| Local Institution - 072 | Cincinnati | Ohio | 45267-0558 | — |
| University of Cincinnati Cancer Center | Cincinnati | Ohio | 45267 | — |
| Providence Cancer Institute | Portland | Oregon | 97213 | — |
| Lifespan Cancer Institute | Providence | Rhode Island | 02903 | — |
| Local Institution - 0001 | Providence | Rhode Island | 02903 | — |
| Local Institution - 164 | Dallas | Texas | 75230 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75251 | — |
| MD Anderson Cancer Center Thoracic-Head & Neck Med Onc | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05025085, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2025 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05025085 live on ClinicalTrials.gov.